Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853306 | 0.81 | TDO2 (0.49) | TDO2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19454936 | 0.80 | TDO2 (0.48) | TDO2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29516737 | 0.80 | PIM1 (0.42) | TDO2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1461869 | 0.78 | CYP11B2 (0.48) | TDO2CYP1A2CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL9988948 | 0.77 | CYP1A2 (0.44) | TDO2CYP1A2CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL19449824 | 0.76 | TDO2 (0.45) | TDO2CYP1A2CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL15205734 | 0.76 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31074188 | 0.76 | TDO2 (0.48) | TDO2CYP1A2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL14995793 | 0.76 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL854398 | 0.75 | MAPT (0.57) | TDO2CYP1A2CYP3A4TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | TDO2 638/4885GRIN2D 3021/4885GRIN3B 3711/4885 |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | TDO2 3108/4885GRIN2D 909/4885GRIN3B 343/4885 |
| US-20170291910-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | TDO2 3108/4885GRIN2D 909/4885GRIN3B 343/4885 |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | TDO2 183/4885GRIN2D 4389/4885GRIN3B 4101/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | TDO2 3005/4885GRIN2D 954/4885GRIN3B 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.